DIRECT CARRIER TESTING OF HEMOPHILIA-B BY SSCP

被引:0
|
作者
MARTINEZ, PA [1 ]
ROMEY, MC [1 ]
SCHVED, JF [1 ]
GRIS, JC [1 ]
DEMAILLE, J [1 ]
CLAUSTRES, M [1 ]
机构
[1] HOP G DOUMERGUE,HEMATOL LAB,F-30000 NIMES,FRANCE
来源
CLINICAL AND LABORATORY HAEMATOLOGY | 1994年 / 16卷 / 01期
关键词
HEMOPHILIA B; CARRIER TESTING; DNA DIAGNOSIS; SSCP ANALYSIS;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Haemophilia B is due to multiple molecular defects in the factor IX gene. Most of them are single base substitutions, and can now be identified by direct sequencing of the coding sequence of the factor IX gene, preceded or not by a screening strategy. In some instances the mutation alters an enzyme recognition site and this allows rapid and accurate carrier testing and prenatal diagnosis in the affected pedigree. This was not the case for the previously described nt 31119 (G- >A) mutation that we found in an extended haemophilia B pedigree, during the search for mutations in the factor IX gene in patients from Southern France. We first detected this mutation by single stranded conformation polymorphism (SSCP) and then identified it by DNA sequencing. Carriership could be easily determined in the females of the pedigree by analysis of the SSCP patterns. Our results indicate that the SSCP analysis of amplified genomic DNA fragments can be successfully used as a diagnosis approach for direct carrier testing and prenatal diagnosis.
引用
收藏
页码:15 / 20
页数:6
相关论文
共 50 条
  • [21] HETERODUPLEX SCREENING FOR MOLECULAR DEFECTS IN FACTOR-IX GENES FROM HEMOPHILIA-B FAMILIES
    CHEN, SH
    SCHOOF, JM
    WEINMANN, AF
    THOMPSON, AR
    BRITISH JOURNAL OF HAEMATOLOGY, 1995, 89 (02) : 409 - 412
  • [22] TREATMENT OF HEMOPHILIA-B - SERENDIPITOUS USE OF CONTINUOUS-INFUSION COAGULATION FACTOR-IX
    GOLDSMITH, JC
    GORDON, EM
    THROMBOSIS RESEARCH, 1993, 70 (03) : 265 - 267
  • [23] HEMOPHILIA-B IN A 46,XX FEMALE PROBABLY CAUSED BY NON-RANDOM-X INACTIVATION
    WADELIUS, C
    LINDSTEDT, M
    PIGG, M
    EGBERG, N
    PETTERSSON, U
    ANVRET, M
    CLINICAL GENETICS, 1993, 43 (01) : 1 - 4
  • [24] MYOCARDIAL-INFARCTION AFTER FEIBA THERAPY IN A HEMOPHILIA-B PATIENT WITH A FACTOR-IX INHIBITOR
    MIZON, P
    GOUDEMAND, J
    JUDE, B
    MAREY, A
    ANNALS OF HEMATOLOGY, 1992, 64 (06) : 309 - 311
  • [25] RESULTS IN 3 AUSTRALIAN HEMOPHILIA-B PATIENTS WITH HIGH-RESPONDING INHIBITORS TREATED WITH THE MALMO MODEL
    NILSSON, IM
    BERNTORP, E
    RICKARD, KA
    HAEMOPHILIA, 1995, 1 (01) : 59 - 66
  • [26] CARRIER DETECTION IN DMD FAMILIES WITH POINT MUTATIONS, USING PCR-SSCP AND DIRECT SEQUENCING
    LENK, U
    HANKE, R
    SPEER, A
    NEUROMUSCULAR DISORDERS, 1994, 4 (5-6) : 411 - 418
  • [27] NEW TREATMENT STRATEGY FOR HEMOPHILIA-B - INCORPORATION OF FACTOR-IX INTO RED-CELL GHOSTS
    GOLDSMITH, JC
    ROER, MES
    ORRINGER, EP
    AMERICAN JOURNAL OF HEMATOLOGY, 1979, 7 (02) : 119 - 125
  • [28] A WOMAN WITH SPORADIC HEMOPHILIA-B DIE BECAUSE OF CEREBRAL BLEEDING: A Rare Case in Bali-Indonesia
    Suega, Ketut
    BALI MEDICAL JOURNAL, 2015, 4 (02) : 61 - 67
  • [29] HIGH-PURITY FACTOR-IX CONCENTRATES FOR TREATMENT OF HEMOPHILIA-B - RELATIVE PURITY AND THROMBOGENIC POTENTIAL
    LIMENTANI, SA
    GOWELL, KP
    DEITCHER, SR
    ACTA HAEMATOLOGICA, 1995, 94 : 12 - 17
  • [30] 5 NOVEL POINT MUTATIONS - 2 CAUSING HEMOPHILIA-B AND 3 CAUSING FACTOR-X DEFICIENCY
    ODOM, MW
    LEONE, G
    DESTEFANO, V
    MONTIEL, MM
    BOLAND, EJ
    ANDERSON, J
    JAGADEESWARAN, P
    MOLECULAR AND CELLULAR PROBES, 1994, 8 (01) : 63 - 65